Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05263570 | The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World. | recruiting | — | 200 | Shengjing HospitalOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05537129 | Laparoscopic vs Open Total Gastrectomy for Gastric Cancer | recruiting | N/A | 600 | Fudan UniversityOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05534906 |
| The Detection of Small Early Liver Cancer With Natural History Follow up(SELINA) |
| recruiting |
| — |
| 250 |
| University of OxfordOTHER |
| 1 |
| Sep 10, 2022 |
| clinicaltrials |
| NCT05339568 | Patient's Whole Process Follow-up Management(HOPE-1)(HOPE-1) | recruiting | — | 1,268 | Qianfoshan HospitalOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05529615 | Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer(CTAC) | recruiting | N/A | 2,684 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT04389086 | Induction Chemotherapy for Locally Recurrent Rectal Cancer(PelvEx II) | recruiting | Phase 3 | 364 | Catharina Ziekenhuis EindhovenOTHER | 5 | Sep 6, 2022 | clinicaltrials |
| NCT05528055 | A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 122 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05276037 | Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates | recruiting | — | 350 | University of LiegeOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05524090 | PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer(PREOPANC-4) | recruiting | — | 223 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05334277 | Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA(FOCUS-C) | recruiting | Phase 2 | 280 | Sun Yat-sen UniversityOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT04699292 | International Prospective Registry on Local Treatment Approaches in MLS | recruiting | — | 300 | The Netherlands Cancer InstituteOTHER | 1 | Aug 30, 2022 | clinicaltrials |
| NCT05521204 | Olverembatinib for FGFR1-rearranged Neoplasms | recruiting | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 30, 2022 | clinicaltrials |
| NCT04442412 | Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy(FIL_PREVID) | recruiting | Phase 3 | 430 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05518383 | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | recruiting | Phase 4 | 300 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT04486495 | Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer(MINIMAX) | recruiting | — | 549 | Maastricht University Medical CenterOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT04875585 | Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC(INNWOP1) | recruiting | Phase 2 | 33 | Medical University InnsbruckOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05514275 | Radiotherapy Combined With Endostatin and Capecitabine for NPC | recruiting | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05030805 | Transcriptional Map of Ovarian Cancer at the Single Cell Level(Ova-seq) | recruiting | — | 50 | University Hospital, Strasbourg, FranceOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05404906 | AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission | recruiting | Phase 2 / Phase 3 | 124 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05507411 | Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC(WATCHER) | recruiting | Phase 2 | 100 | Zhejiang Cancer HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT02859402 | Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas(RRTCLAlloSCT) | recruiting | Phase 2 | 34 | Keimyung University Dongsan Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05506332 | Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 10 | University Hospital, AntwerpOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05506410 | A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma | recruiting | — | 100 | Zhengzhou UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04403867 | The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study.(ITCMicroUtCa) | recruiting | — | 500 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05503667 | Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma | recruiting | Phase 2 | 96 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT04926584 | Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option(KOMPASSneo) | recruiting | — | 50 | Klinikum EsslingenOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05406999 | Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | recruiting | Phase 2 | 900 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT03789253 | Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer | recruiting | — | 300 | National Taiwan University HospitalOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT05500118 | Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU | recruiting | — | 120 | Shenzhen Maternity & Child Healthcare HospitalOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT05498064 | A Real World Study of Ensartinib in Advanced ALK-positive NSCLC | recruiting | — | 490 | Peking Union Medical College HospitalOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05397769 | Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial. | recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04138212 | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)(HCHTOG1903) | recruiting | Phase 3 | 456 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05494021 | China Lung Cancer Screening (CLUS) Study Version 3.0 | recruiting | N/A | 100,000 | Shanghai Chest HospitalOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04698252 | Local Therapy for ER/PR-positive Oligometastatic Breast Cancer(LARA) | recruiting | Phase 2 | 74 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT04914026 | MicroRNA as Markers in Testicular Cancer | recruiting | — | 350 | Haukeland University HospitalOTHER | 2 | Aug 8, 2022 | clinicaltrials |
| NCT05491395 | Hypofractionated Radiotherapy in Breast Cancer Patients With Prosthetic Reconstruction(PROMART) | recruiting | N/A | 120 | Barretos Cancer HospitalOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT04985032 | Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT) | recruiting | — | 200 | RPCR, Inc.OTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT04681469 | Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC(PRIME) | recruiting | Phase 2 | 49 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05434026 | Chinese Colorectal Cancer Database(CCCD) | recruiting | — | 200,000 | Beijing Friendship HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05366478 | A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 15 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05025813 | Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma(DESQUAMATE) | recruiting | Phase 2 | 27 | Queensland HealthOTHER_GOV | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05300269 | SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | recruiting | Phase 2 | 73 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04520074 | Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) | recruiting | Phase 3 | 590 | Fudan UniversityOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05469022 | Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy | recruiting | Phase 2 | 40 | Konkuk University Medical CenterOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT05466565 | Antiviral Therapy for Patients With Liver Cancer After Surgery | recruiting | — | 360 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05415631 | Augmented Bladder Tumor Detection Using Real Time Based Artificial Intelligence(Bladder-PAD) | recruiting | — | 500 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05305092 | Assessment of Brain Cognitive Impairment in Breast Cancer | recruiting | — | 90 | Tang-Du HospitalOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT05447169 | Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening | recruiting | — | 11,625 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05392413 | Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody | recruiting | — | 200 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Sep 13, 2022source: clinicaltrials